Literature DB >> 22633099

Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis.

Federico Salamone1, Fabio Galvano, Francesco Cappello, Andrea Mangiameli, Ignazio Barbagallo, Giovanni Li Volti.   

Abstract

Nonalcoholic steatohepatitis (NASH) is associated with increased liver-related mortality. Disturbances in hepatic lipid homeostasis trigger oxidative stress and inflammation (ie, lipotoxicity), leading to the progression of NASH. This study aimed at identifying whether silibinin may influence the molecular events of lipotoxicity in a mouse model of NASH. Eight-week-old db/db mice were fed a methionine-choline deficient (MCD) diet for 4 weeks and treated daily with silibinin (20 mg/kg intraperitoneally) or vehicle. Liver expression and enzyme activity of stearoyl-CoA desaturase-1 and acyl-CoA oxidase, and expression of liver fatty acid-binding protein were assessed. Hepatic levels of reactive oxygen species, thiobarbituric acid-reactive substances (TBARS), 3-nitrotyrosine (3-NT), inducible nitric oxide synthase (iNOS), and nuclear factor kappa B (NFkB) activities were also determined. Silibinin administration decreased serum alanine aminotransferase and improved liver steatosis, hepatocyte ballooning, and lobular inflammation in db/db mice fed an MCD diet. Gene expression and activity of stearoyl-CoA desaturase-1 were reduced in db/db mice fed an MCD diet compared with lean controls and were increased by silibinin; moreover, silibinin treatment induced the expression and activity of acyl-CoA oxidase and the expression of liver fatty acid-binding protein. Vehicle-treated animals displayed increased hepatic levels of reactive oxygen species and TBARS, 3-NT staining, and iNOS expression; silibinin treatment markedly decreased reactive oxygen species and TBARS and restored 3-NT and iNOS to the levels of control mice. db/db mice fed an MCD diet consistently had increased NFkB p65 and p50 binding activity; silibinin administration significantly decreased the activity of both subunits. Silibinin treatment counteracts the progression of liver injury by modulating lipid homeostasis and suppressing oxidative stress-mediated lipotoxicity and NFkB activation in experimental NASH.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22633099     DOI: 10.1016/j.trsl.2011.12.003

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  36 in total

1.  Dietary silymarin supplementation promotes growth performance and improves lipid metabolism and health status in grass carp (Ctenopharyngodon idellus) fed diets with elevated lipid levels.

Authors:  Peizhen Xiao; Hong Ji; Yuantu Ye; Baotong Zhang; Yongsheng Chen; Jingjing Tian; Pin Liu; Liqiao Chen; Zhenyu Du
Journal:  Fish Physiol Biochem       Date:  2016-09-08       Impact factor: 2.794

2.  Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.

Authors:  S DebRoy; N Hiraga; M Imamura; C N Hayes; S Akamatsu; L Canini; A S Perelson; R T Pohl; S Persiani; S L Uprichard; C Tateno; H Dahari; K Chayama
Journal:  J Viral Hepat       Date:  2016-06-08       Impact factor: 3.728

3.  Genetic ablation of macrohistone H2A1 leads to increased leanness, glucose tolerance and energy expenditure in mice fed a high-fat diet.

Authors:  F Sheedfar; M Vermeer; V Pazienza; J Villarroya; F Rappa; F Cappello; G Mazzoccoli; F Villarroya; H van der Molen; M H Hofker; D P Koonen; M Vinciguerra
Journal:  Int J Obes (Lond)       Date:  2014-05-21       Impact factor: 5.095

4.  Human germline hedgehog pathway mutations predispose to fatty liver.

Authors:  Maria J Guillen-Sacoto; Ariel F Martinez; Yu Abe; Paul Kruszka; Karin Weiss; Joshua L Everson; Ramon Bataller; David E Kleiner; Jerrold M Ward; Kathleen K Sulik; Robert J Lipinski; Benjamin D Solomon; Maximilian Muenke
Journal:  J Hepatol       Date:  2017-06-21       Impact factor: 25.083

Review 5.  A comprehensive review on phytochemicals for fatty liver: are they potential adjuvants?

Authors:  Taís Menezes do Moinho; Sandro Leão Matos; Carla R O Carvalho
Journal:  J Mol Med (Berl)       Date:  2022-01-07       Impact factor: 4.599

6.  Cannabinoid receptor 1 promotes hepatic lipid accumulation and lipotoxicity through the induction of SREBP-1c expression in zebrafish.

Authors:  Wan-Yu Pai; Chia-Chun Hsu; Chi-Yu Lai; Trent-Zarng Chang; Yu-Lun Tsai; Guor Mour Her
Journal:  Transgenic Res       Date:  2013-01-12       Impact factor: 2.788

7.  Quantitative proteomics analysis based on tandem mass tag labeling coupled with labeling coupled with liquid chromatography-tandem mass spectrometry discovers the effect of silibinin on non-alcoholic fatty liver disease in mice.

Authors:  Yichao Wang; Hang Zhao; Liying Yang; He Zhang; Xian Yu; Wenjie Fei; Yunfeng Zhen; Zhe Gao; Shuchun Chen; Luping Ren
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

8.  Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model.

Authors:  Yuichi Nozaki; Koji Fujita; Koichiro Wada; Masato Yoneda; Takaomi Kessoku; Yoshiyasu Shinohara; Kento Imajo; Yuji Ogawa; Makoto Nakamuta; Satoru Saito; Naohiko Masaki; Yoji Nagashima; Yasuo Terauchi; Atsushi Nakajima
Journal:  BMC Gastroenterol       Date:  2015-04-01       Impact factor: 3.067

Review 9.  Targeting Inflammation in Cancer Prevention and Therapy.

Authors:  Jelena Todoric; Laura Antonucci; Michael Karin
Journal:  Cancer Prev Res (Phila)       Date:  2016-11-10

10.  Immunopositivity for histone macroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma.

Authors:  Francesca Rappa; Azzura Greco; Christine Podrini; Francesco Cappello; Michelangelo Foti; Lucie Bourgoin; Marion Peyrou; Arianna Marino; Nunzia Scibetta; Roger Williams; Gianluigi Mazzoccoli; Massimo Federici; Valerio Pazienza; Manlio Vinciguerra
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.